ClinicalTrials.gg
CompletedNCT03923738Updated Dec 22, 2021Results posted

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Tocilizumab (TCZ) Administered to Participants With Giant Cell Arteritis (GCA).

A Phase 1 interventional study of Tocilizumab in Giant Cell Arteritis, sponsored by Hoffmann-La Roche. Completed at 2 sites in Switzerland. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2021-12-22.

Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing tocilizumab in Giant Cell Arteritis — 2 open to participants now, 3 under way, 1 of them phase 3. tocilizumab · Giant Cell Arteritis.

Enrollment
9th of 12
24 · median 44
Started
2019
the only one that year
Phase 1
2 of 12
none open now
Registered
7th of 12
by date
Lead sponsor
3 of 12
Hoffmann-La Roche

Among the 12 studies testing tocilizumab in Giant Cell Arteritis, this one is the 9th largest by enrollment, is the only one that started in 2019, is one of 2 in phase 1, and was the 7th registered.

Giant Cell Arteritis

149 studies on the registry are indexed under Giant Cell Arteritis; 50 are open to participants now.

Browse Giant Cell Arteritis studies →

Open to participants now

2 of the 12 studies testing tocilizumab in Giant Cell Arteritis are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About tocilizumab

tocilizumab: first FDA approval 2010 (ACTEMRA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 36 Giant Cell Arteritis studies recruiting now, 34 (94%) set no upper age limit and none (0%) stop at 75 or younger; 4 take children under 18; 9 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing tocilizumab in Giant Cell Arteritis, or all of them as a file.
02

Study summary

This study will evaluate the pharmacokinetics, pharmacodynamics, and safety of two dose levels of tocilizumab (TCZ) administered by intravenous (IV) infusion every 4 weeks (Q4W) to participants with giant cell arteritis (GCA).

03

Conditions studied

  • Giant Cell Arteritis

Browse trials for

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of GCA as classified according to protocol-specified criteria;
  • Participants entering Period 1 must be receiving treatment with TCZ 8 mg/kg IV Q4W.

Exclusion criteria

Exclusion Criteria:

  • Treatment with any other agent besides TCZ within 12 weeks (or 5 half-lives of the investigational drug, whichever is longer) prior to screening;
  • Evidence of serious uncontrolled disease;
  • Known active current or history of recurrent bacterial, viral, fungal, mycobacterial, or other infections;
  • Active TB requiring treatment within the previous 3 years.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    TCZ IV Q4W

    Participants will receive up to 6 doses of Dose 1 of TCZ IV Q4W followed by up to 6 doses of Dose 2 of TCZ IV Q4W.

    Drug: Tocilizumab

Interventions

  • TCZ will be administered by IV infusion at two dose levels Q4W. The maximum dose of TCZ that will be administered is 800 mg. The dose of TCZ infusion will be calculated on the basis of body weight measured prior to each infusion.

    Also known as: RoActemra/Actemra

06

What researchers measure

Primary outcomes

  1. Maximum Serum Concentration (Cmax) of TCZ

    Time frame: Baseline; Weeks 4, 8, 12, 16-24

  2. Trough Serum Concentration (Ctrough) of TCZ at Steady State

    Time frame: Baseline; Weeks 4, 8, 12, 16-24

  3. Area Under the Concentration-Time Curve Over the Dosing Interval of 4 Weeks (AUC4weeks) of TCZ at Steady State

    Time frame: Baseline; Weeks 4, 8, 12, 16-24

  4. Percentage of Participants With Adverse Events

    Time frame: Baseline - Day 151

Secondary outcomes

  1. Serum Concentration of Interleukin-6 (IL-6)

    Time frame: Baseline; Weeks 12, 16, 20, 24

  2. Serum Concentration of Soluble Interleukin-6 Receptor (sIL-6R)

    Time frame: Baseline; Weeks 12, 16, 20, 24

  3. Serum Concentration of C-Reactive Protein (CRP)

    Time frame: Baseline; Weeks 4, 8, 12, 16-24

  4. Erythrocyte Sedimentation Rate (ESR)

    Time frame: Baseline; Weeks 4, 8, 12, 16-24

07

Results

Posted Dec 22, 2021

Participant flow

Period 1
Participant flow — Period 1
MilestoneTCZ IV Q4W
Started24
Completed22
Not completed2
Withdrew: Adverse event1
Withdrew: Withdrawal by subject1
Period 2
Participant flow — Period 2
MilestoneTCZ IV Q4W
Started22
Completed22
Not completed0

Outcome measures

PrimaryMaximum Serum Concentration (Cmax) of TCZ
Time frame:
Baseline; Weeks 4, 8, 12, 16-24
Reported as:
Median · ug/mL
Maximum Serum Concentration (Cmax) of TCZ
ug/mLTCZ IV Q4W 7 mg/kgTCZ IV Q4W 6 mg/kg
Maximum Serum Concentration (Cmax) of TCZ197 (118 to 352)178 (115 to 320)
PrimaryTrough Serum Concentration (Ctrough) of TCZ at Steady State
Time frame:
Baseline; Weeks 4, 8, 12, 16-24
Reported as:
Median · ug/mL
Trough Serum Concentration (Ctrough) of TCZ at Steady State
ug/mLTCZ IV Q4W 7 mg/kgTCZ IV Q4W 6 mg/kg
Trough Serum Concentration (Ctrough) of TCZ at Steady State37.2 (6.59 to 69.0)22.7 (3.38 to 54.5)
PrimaryArea Under the Concentration-Time Curve Over the Dosing Interval of 4 Weeks (AUC4weeks) of TCZ at Steady State
Time frame:
Baseline; Weeks 4, 8, 12, 16-24
Reported as:
Median · day*ug/mL
Area Under the Concentration-Time Curve Over the Dosing Interval of 4 Weeks (AUC4weeks) of TCZ at Steady State
day*ug/mLTCZ IV Q4W 7 mg/kgTCZ IV Q4W 6 mg/kg
Area Under the Concentration-Time Curve Over the Dosing Interval of 4 Weeks (AUC4weeks) of TCZ at Steady State2130 (1120 to 4300)1610 (921 to 3070)
PrimaryPercentage of Participants With Adverse Events
Time frame:
Baseline - Day 151
Reported as:
Number · Percentage of Participants
Percentage of Participants With Adverse Events
Percentage of ParticipantsTCZ IV Q4W 7 mg/kgTCZ IV Q4W 6 mg/kg
Percentage of Participants With Adverse Events79.240.9
SecondarySerum Concentration of Interleukin-6 (IL-6)
Time frame:
Baseline; Weeks 12, 16, 20, 24
Reported as:
Mean · pg/mL
Serum Concentration of Interleukin-6 (IL-6)
pg/mLTCZ IV Q4W 7 mg/kgTCZ IV Q4W 6 mg/kg
Baseline57.80 ± 61.14939.46 ± 25.989
Week 1256.03 ± 84.98849.73 ± 81.718
Week 1697.57 ± 277.40943.04 ± 54.232
Week 2038.11 ± 21.14746.97 ± 61.454
Week 24111.00 ± NA—
SecondarySerum Concentration of Soluble Interleukin-6 Receptor (sIL-6R)
Time frame:
Baseline; Weeks 12, 16, 20, 24
Reported as:
Mean · ng/mL
Serum Concentration of Soluble Interleukin-6 Receptor (sIL-6R)
ng/mLTCZ IV Q4W 7 mg/kgTCZ IV Q4W 6 mg/kg
Baseline665.8 ± 153.81671.3 ± 152.69
Week 12680.8 ± 183.84670.9 ± 175.92
Week 16654.6 ± 173.26651.7 ± 136.95
Week 20663.8 ± 147.92690.0 ± 215.91
Week 24519.0 ± NA—
SecondarySerum Concentration of C-Reactive Protein (CRP)
Time frame:
Baseline; Weeks 4, 8, 12, 16-24
Reported as:
Mean · mg/L
Serum Concentration of C-Reactive Protein (CRP)
mg/LTCZ IV Q4W 7 mg/kgTCZ IV Q4W 6 mg/kg
Baseline0.615 ± 1.16450.356 ± 0.2486
Week 40.511 ± 0.75380.591 ± 1.0646
Week 80.426 ± 0.36870.403 ± 0.3217
Week 120.467 ± 0.56940.359 ± 0.2585
Week 160.344 ± 0.27950.382 ± 0.3726
Week 170.409 ± 0.25330.409 ± 0.4521
Week 180.374 ± 0.29940.389 ± 0.3168
Week 190.387 ± 0.28010.388 ± 0.3348
Week 200.340 ± 0.21720.416 ± 0.2938
Week 210.200 ± 0.0000—
Week 220.200 ± 0.0000—
Week 230.203 ± 0.0058—
Week 240.200 ± 0.0000—
SecondaryErythrocyte Sedimentation Rate (ESR)
Time frame:
Baseline; Weeks 4, 8, 12, 16-24
Reported as:
Mean · mm/h
Erythrocyte Sedimentation Rate (ESR)
mm/hTCZ IV Q4W 7 mg/kgTCZ IV Q4W 6 mg/kg
Baseline6.1 ± 6.725.6 ± 5.01
Week 44.7 ± 3.385.6 ± 4.11
Week 87.2 ± 12.255.0 ± 3.13
Week 125.9 ± 5.306.5 ± 5.27
Week 165.9 ± 4.565.1 ± 4.32
Week 175.2 ± 3.845.0 ± 4.64
Week 184.4 ± 3.994.8 ± 3.01
Week 194.3 ± 2.645.0 ± 5.20
Week 207.1 ± 6.195.6 ± 5.04
Week 214.5 ± 3.54—
Week 225.3 ± 3.79—
Week 234.0 ± 3.00—
Week 243.7 ± 1.53—

Adverse events

Collected over Baseline - Day 151. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TCZ IV 7 mg/kg Q4W0/24 (0%)3/24 (12.5%)6/24 (25%)
TCZ IV 6 mg/kg Q4W0/22 (0%)1/22 (4.5%)3/22 (13.6%)
Most frequent serious events
Most frequent serious events
EventTCZ IV 7 mg/kg Q4WTCZ IV 6 mg/kg Q4W
Vertigo positionalEar and labyrinth disorders0/241/22
Lower gastrointestinal haemorrhageGastrointestinal disorders1/240/22
Pneumonia pneumococcalInfections and infestations1/240/22
Aortic aneurysm ruptureVascular disorders1/240/22
Most frequent other events
Most frequent other events
EventTCZ IV 7 mg/kg Q4WTCZ IV 6 mg/kg Q4W
NasopharyngitisInfections and infestations3/241/22
Respiratory tract infection viralInfections and infestations1/242/22
Upper respiratory tract infectionInfections and infestations2/240/22

Baseline characteristics

Age, Continuous
Age, Continuous(Years)TCZ IV Q4W
Mean67.9 ± 8.1
Sex: Female, Male
Sex: Female, Male(Participants)TCZ IV Q4W
Female15
Male9
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)TCZ IV Q4W
Hispanic or Latino0
Not Hispanic or Latino24
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)TCZ IV Q4W
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American0
White23
More than one race0
Unknown or Not Reported0
08

Study locations

2 sites
  • Universitätsspital Basel; Rheumatologie
    Basel, 4031, Switzerland
  • Inselspital Bern; Rheumatologie; Klinische Immunologie und Allergologie
    Bern, 3010, Switzerland
09

References and documents

Publications

  • Schmitt C, Brockwell L, Giraudon M, Zucchetto M, Christ L, Bannert B, Daikeler T, Villiger PM. Intravenous tocilizumab for the treatment of giant cell arteritis: a phase Ib dose-ranging pharmacokinetic bridging study. Arthritis Res Ther. 2022 Jun 4;24(1):133. doi: 10.1186/s13075-022-02815-9. PubMed 35659282 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.clinicalstudydatarequest.com). Further details on Roche's criteria for eligible studies are available here (https://clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-Roche.aspx). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2019 to primary completion in Nov 2020, 15 months.

Results were first posted in Dec 2021, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 19, 2019
First posted
Apr 23, 2019
StartActual
Aug 5, 2019
Primary completionActual
Nov 12, 2020
CompletionActual
Nov 12, 2020
Results first posted
Dec 22, 2021
Last update
Dec 22, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 22, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03923738
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Apr 23, 2019
Start date
Aug 5, 2019
Primary completion
Nov 12, 2020
Completion
Nov 12, 2020
Results posted
Dec 22, 2021
Last update
Dec 22, 2021

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tocilizumab

Start the discussion